Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction

Journal of the American College of Cardiology
Amir HalkinRoxana Mehran

Abstract

We examined the prognostic implications of the absolute level and rate of increase of creatine kinase (CK) elevation after primary percutaneous coronary intervention (PCI). Peak creatine kinase (CK(peak)) and the rate of CK increase are related to reperfusion success and clinical outcomes after thrombolytic therapy for acute myocardial infarction (AMI). The utility of routine serial CK monitoring after primary PCI, in which normal antegrade blood flow is restored in most patients, is unknown. In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 1,529 patients with AMI randomized to either stenting or balloon angioplasty, each with or without abciximab, had CK levels determined at baseline and at 8 +/- 1 h, 16 +/- 1 h, and 24 +/- 1 h after PCI. The CK(peak) occurred at baseline in 3.9% of patients, at 8 +/- 1 h in 69.6%, at 16 +/- 1 h in 20.0%, and at 24 +/- 1 h in 6.5%. The CK levels at all post-procedural time points were significantly higher in patients who died compared with the one-year survivors, as was CK(peak) (mean, 2,865 U/l vs. 1,885 U/l, respectively, p < or = 0.001). By multivariate analysis, CK(peak) was a significant predictor of one-year mortality (hazard ...Continue Reading

References

Apr 1, 1978·The Journal of Clinical Investigation·S F VatnerP R Maroko
Oct 1, 1972·Circulation·B E SobelR D Yoder
Jun 1, 1995·Journal of the American College of Cardiology·J J MurrayM B Forman
Nov 1, 1996·European Heart Journal·D R HoldrightH Swanton
Jan 5, 2002·Journal of the American College of Cardiology·Stefano SavonittoUNKNOWN GUSTO-IIb Investigators
Mar 29, 2002·The New England Journal of Medicine·Gregg W StoneUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
Sep 15, 2004·Journal of the American College of Cardiology·Michael G McLaughlinUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial

❮ Previous
Next ❯

Citations

Jul 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Tetsuya TatsumiHiroaki Matsubara
Apr 11, 2009·QJM : Monthly Journal of the Association of Physicians·A HalkinS Behar
Aug 19, 2008·Journal of Interventional Cardiology·Kishore HarjaiSrinivas Devarakonda
Oct 26, 2012·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Erkan AyhanCharles Michael Gibson
Apr 18, 2007·The American Journal of Cardiology·Abhiram PrasadBernard J Gersh
Mar 29, 2008·American Heart Journal·Mark B NienhuisUNKNOWN Zwolle Myocardial Infarction Study Group
Aug 11, 2006·International Journal of Cardiology·Giuseppe De LucaUNKNOWN Ongoing Tirofiban In Myocardial Infarction Evaluation (On-TIME) study group
Jul 17, 2007·Journal of the American College of Cardiology·Simon R DixonWilliam W O'Neill
May 5, 2009·International Journal of Cardiology·Peter Riis HansenJawdat Abdulla
Jan 27, 2015·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Werner MohlFrank Rattay
Mar 20, 2015·Research in Cardiovascular Medicine·Shokoufeh HajsadeghiMaryam Mohsenian
Jan 20, 2017·Journal of Atherosclerosis and Thrombosis·Tomoaki NatsukawaIichiro Shimomura
Dec 25, 2009·Circulation. Cardiovascular Interventions·Gregg W StoneUNKNOWN AMIHOT-II Trial Investigators
May 12, 2007·Clinical Cardiology·Hiroyasu UedaMinoru Yoshiyama
Jul 18, 2020·Open Heart·Lizzy Maritza Brewster, Jim Fernand
Feb 15, 2021·The American Journal of Emergency Medicine·Yoshifumi MizuguchiToshihisa Anzai

❮ Previous
Next ❯